Can-Fite Seeks Veterinary Partnerships for Cancer Drug Namodenoson at BioFIT 2025
核心洞察
Can-Fite BioPharma will participate in BioFIT 2025 to advance veterinary partnerships for Namodenoson, its Phase III anti-cancer drug candidate with demonstrated strong anti-tumor activity and excellent safety profile.
The company aims to explore collaborations with major animal health companies including Elanco Animal Health (搜索) and Zoetis to bring Namodenoson into veterinary oncology development.
Veterinary oncology represents a significant market opportunity projected to reach $3.1 billion by 2030, building on Can-Fite's successful $325 million partnership with Vetbiolix (搜索) for Piclidenoson.
Can-Fite BioPharma Ltd. announced its participation in BioFIT 2025, scheduled for December 2-3, 2025, in Strasbourg, France, where the company will seek new veterinary partnerships for its Phase III anti-cancer drug candidate Namodenoson. The biotechnology company aims to capitalize on the growing veterinary oncology market, which is projected to reach $3.1 billion by 2030.
Strategic Focus on Veterinary Oncology
At BioFIT 2025, Can-Fite will hold partnering meetings with major multinational animal health companies, including Elanco Animal Health (搜索) and Zoetis, to explore collaboration opportunities for bringing Namodenoson into veterinary development. The company's strategy builds on its previous success at the conference, which led to a partnership with Vetbiolix (搜索) for Piclidenoson worth an estimated $325 million in potential royalty revenues.
"Our previous participation at BioFIT led directly to our successful partnership with Vetbiolix (搜索) for Piclidenoson for the treatment of osteoarthritis in dogs and cats, an agreement potentially worth an estimated $325 million in royalty revenues for Can-Fite," stated Dr. Sari Fishman, Can-Fite's VP of Business Development. "As we return this year, we look forward to advancing new collaborations around Namodenoson and expanding our veterinary pipeline."
Namodenoson's Clinical Profile
Namodenoson has demonstrated strong anti-tumor activity, complete response in human liver cancer patients, and an excellent safety profile, making it a compelling candidate for veterinary oncology applications. The drug candidate is currently being evaluated in human clinical trials, including a Phase III liver cancer trial and a Phase II pancreatic cancer study.
The company's experience spans over 1,600 patients in clinical studies to date, providing substantial safety data for the drug candidate. Namodenoson has been granted Orphan Drug Designation in both the U.S. and Europe, as well as Fast Track Designation as a second-line treatment for hepatocellular carcinoma by the U.S. Food and Drug Administration.
Expanding Veterinary Portfolio
Can-Fite's veterinary strategy extends beyond Namodenoson. The company's Piclidenoson is currently in development for the treatment of osteoarthritis in pets, with clinical studies showing efficacy in dogs. This represents a $3 billion market opportunity, according to the company.
The biotechnology company is advancing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma in human studies.
BioFIT 2025 is described as a major European conference focused on life sciences, bringing together academia, industry, and investors to facilitate technology transfer, early-stage collaborations, and investment in biotech and medtech sectors.